NeuroBo Pharmaceuticals Inc expected to post a loss of $1.12 a share - Earnings Preview

MetaVia

05/08/2024 14:29

* NeuroBo Pharmaceuticals Inc  NRBO.OQ   NRBO.O  is expected
to show no change in quarterly revenue when it reports 
results on August 7 (estimated) for the period ending June
30 2024
    * 
    * ​LSEG's mean analyst estimate for NeuroBo Pharmaceuticals
Inc is
for a loss of $1.12 per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 230.4% in the last three months. ​
    * Wall Street's median 12-month price target for NeuroBo
Pharmaceuticals Inc is $25.00​, above​ its last closing price
of $3.99. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -3.79       -3.63      -1.32     Beat    63.6
 Jan. 1 2024   -0.79       -0.78      -2.28     Missed  -190.4
 Sep. 30 2023  -0.86       -0.86      -0.72     Beat    15.9​
 Jan. 1 0001   -1.01       -1.01      -0.16     Beat    84.1
 ​​Mar.                    -5.04      -0.77     Beat    84.8
 31 2023                                                
 Dec. 31 2022  -9.60       -9.60      -14.56    Missed  -51.7​
 This summary was machine generated August 5 at 13:29 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)